Hepatits B

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has decided to discontinue the development of EDP-721, an oral Hepatitis B Virus (HBV) RNA destabilizer. The move follows safety signals observed in the single ascending dose part of a Phase 1 study in healthy volunteers. "Despite the...

Beam Therapeutics Inc (NASDAQ: BEAM) has announced preclinical data for its cytosine base editors (CBEs). The data demonstrate the potential of CBEs to reduce viral markers, including hepatitis B surface antigen (HBsAg) expression, and prevent viral rebound of hepatitis B virus (HBV...

Arbutus Biopharma Corporation (NASDAQ: ABUS) and Vaccitech plc (NASDAQ: VACC) have collaborated to evaluate combination treatment for chronic hepatitis B virus who are already receiving standard-of-care nucleos(t)ide reverse transcriptase inhibitor (NrtI) therapy. The...

Vir Biotechnology Inc (NASDAQ: VIR) has announced new data from its ongoing Phase 2 trials of VIR-2218 and Phase 1 studies of VIR-3434 in patients with chronic hepatitis B virus (HBV) infection.  The results were presented at the European Association for the Study of the Liver...

Dynavax Technologies Corporation (NASDAQ: DVAX) has entered into a commercialization agreement with Bavarian Nordic for the marketing and distribution of HEPLISAV B, the Hepatitis B vaccine in Germany, with an expected launch in the fourth quarter of 2021. Financial terms were not...

VBI Vaccines Inc (NASDAQ: VBIV) has announced that results from Phase 3 PROTECT trial of VBI's prophylactic 3-antigen hepatitis B (HBV) vaccine candidate in adults were published in The Lancet Infectious Diseases. The study was designed to compare the immunogenicity and...

Enanta Pharmaceuticals Inc (NASDAQ: ENTA) has announced data from the first two dose cohorts of Part 2 of its Phase 1b study evaluating EDP-514 in chronic hepatitis B virus (HBV) patients already being treated with a nucleoside reverse transcriptase inhibitor (NUC). The data...

Privately-held Brii Biosciences, Vir Biotechnology Inc (NASDAQ: VIR), and VBI Vaccines Inc (NASDAQ: VBIV) have dosed the first patient in a Phase 2 trial evaluating BRII-835 (VIR-2218) in combination with BRII-179 (VBI-2601) for the treatment...

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) develops medicines to treat intractable diseases. The company’s therapies trigger the RNA interference to alter target genes, as a natural process of gene silencing. What Happened Arrowhead announced entrance into a $3.7-billion license and...

In an exclusive interview with Benzinga, director of Investor Relations, Helen Yang, discussed Sinovac’s (NASDAQ: SVA) future opportunities. Sinovac is Chinese biopharmaceutical company which produces, among others, a hepatitis A and B vaccine and is currently preparing to commercialize...